Perceptive Advisors LLC Trims Position in Cumberland Pharmaceuticals Inc. $CPIX

Perceptive Advisors LLC decreased its stake in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 42.2% in the first quarter, HoldingsChannel reports. The institutional investor owned 196,978 shares of the specialty pharmaceutical company’s stock after selling 144,109 shares during the period. Perceptive Advisors LLC’s holdings in Cumberland Pharmaceuticals were worth $640,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its stake in Cumberland Pharmaceuticals by 11.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after acquiring an additional 27,980 shares in the last quarter. Bridgeway Capital Management LLC raised its stake in shares of Cumberland Pharmaceuticals by 2.3% during the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock valued at $631,000 after acquiring an additional 4,200 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Cumberland Pharmaceuticals by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after acquiring an additional 5,653 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Cumberland Pharmaceuticals in the fourth quarter valued at approximately $192,000. Finally, Two Sigma Investments LP boosted its holdings in shares of Cumberland Pharmaceuticals by 16.5% in the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after purchasing an additional 5,326 shares during the period. 15.51% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CPIX has been the topic of several research reports. Wall Street Zen downgraded Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Cumberland Pharmaceuticals Trading Down 0.7%

NASDAQ:CPIX opened at $6.68 on Friday. The firm has a 50-day simple moving average of $6.29 and a 200-day simple moving average of $4.72. Cumberland Pharmaceuticals Inc. has a one year low of $1.85 and a one year high of $8.09. The firm has a market cap of $100.07 million, a P/E ratio of -13.63 and a beta of 0.09. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.79 and a current ratio of 0.95.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings data on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). The firm had revenue of $9.13 million for the quarter, compared to the consensus estimate of $8.50 million. Cumberland Pharmaceuticals had a negative net margin of 17.60% and a negative return on equity of 12.01%.

Cumberland Pharmaceuticals Dividend Announcement

The business also recently announced a dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, July 23rd were given a dividend of $1.50 per share. The ex-dividend date of this dividend was Monday, August 3rd.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.